Today's Rundown Lilly taps AbCellera to get coronavirus drug into clinic in 4 months Rubius scraps lead drug after seeing 'uninterpretable' data Flagship Pioneering combines Torque and Cogen Immune Medicine to rev up R&D Enanta Pharmaceuticals joins the hunt for coronavirus treatments After Kymera's raise, Nurix nabs $120M as it too hones in on clinical work FDA grants Roche coronavirus test emergency green light within 24 hours Attacking drug-resistant tumors with Sierra’s struggling CHK1 blocker Biogen signs on to manufacture clinical supplies for Vir's COVID-19 antibodies EuroBiotech Report—LSP's $600M fund, Versant's Basel expansion, Numab round and Cell Medica FiercePharmaAsia—Legend’s U.S. IPO; U.S. reliance on China drugs; Harbour-Mount Sinai team-up Chutes & Ladders—Fujifilm subsidiary taps Meeson as CEO Featured Story | | | Friday, March 13, 2020 Eli Lilly has teamed up with AbCellera to develop a treatment for the novel coronavirus. The partners aim to have an antibody in the clinic within four months, giving them a shot at contributing to efforts to counter the virus. |
|
|---|
|
| | AlivaMab® Mouse: Establishing the Fastest and Most De-Risked Path from Antibody Drug Discovery to Market. AlivaMab Mouse from Ablexis is a trusted and demonstrably better platform for the successful and efficient discovery of therapeutic-quality antibodies. It is uniquely differentiated to deliver quality, speed and value for antibody drug discovery projects, even the most challenging. Contact us at [email protected] to learn more. ablexis.com |
Top Stories Friday, March 13, 2020 Rubius Therapeutics has pulled the plug on its lead drug after its first use in a phase 1b generated “uninterpretable” data. The data capped off a series of setbacks for the phenylketonuria asset, leading Rubius to stop the trial and focus instead on its oncology and autoimmunity prospects. Friday, March 13, 2020 Major venture capitalist firm Flagship Pioneering has brought together two of its sister biotech companies to create a new, singly focused effort. Friday, March 13, 2020 The hunt is on for a treatment against COVID-19, the disease caused by the novel coronavirus circulating the globe. Some players, like Sanofi and Regeneron, are repurposing older drugs, while others are developing brand-new treatments. Liver specialist Enanta Pharmaceuticals is joining the latter camp. Friday, March 13, 2020 Sanofi- and Gilead Sciences-backed Nurix is following suit with rival biotech Kymera in raising a major cash haul for its protein modulation R&D work. Friday, March 13, 2020 Roche received a green light from the FDA for emergency use of its high-volume coronavirus diagnostic, the first commercially developed test to do so. The agency said it approved the test within 24 hours of receiving the application. Thursday, March 12, 2020 Sierra Oncology deprioritized the development of its CHK1 blocker SRA737 last year, as it steered most of its dwindling resources towards developing a phase 3 myelofibrosis drug that it picked up from Gilead. Now British scientists say SRA737 has the potential to treat several tumor types as part of a combination with another protein blocker. Thursday, March 12, 2020 Biopharma companies across the globe are scrambling to address the novel coronavirus outbreak, which was declared a pandemic on Wednesday. Now, two of them—Biogen and former CEO George Scangos' new company, Vir Biotechnology—are teaming up on an antibody development and manufacturing pact. Thursday, March 12, 2020 In this week's EuroBiotech Report, Bristol-Myers powers LSP fund to $600 million, Versant plots Basel expansion and Vasella invests in Numab. Friday, March 13, 2020 Johnson & Johnson's CAR-T partner Legend Biotech is planning a U.S. IPO. The FDA can't tell how dependent the U.S. is on Chinese supplies of drugs and APIs. Harbour BioMed formed an R&D partnership with Mount Sinai that covers immuno-oncology and the new coronavirus. And more. Friday, March 13, 2020 Fujifilm Diosynth Biotechnologies names Meeson as CEO; Neuronetics head Thatcher steps down; AMAG CMO Krop hits the exit. | | Experts in our field; with 20+ years’ experience in Viral Vector & plasmid DNA (R&D, High Quality and GMP) manufacture for pre-clinical, clinical & commercial supply. Take a virtual tour of our facilities & find out more about our expansion project. |
Enrollment Showcase | | | Presented by: Global EMBA for Healthcare & the Life Sciences, University of Toronto Prepare to step up in your career, build the expertise you need to reshape your organization, and explore opportunities worldwide. |
|
|---|
|
Resources Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Outer Edge Technology See why innovative BioPharma’s are partnering with Cloud Service Provider’s to design, manage and implement cloud strategies to smooth the path to FDA approval and enhance their competitive prowess. Sponsored by: Metabolon Metabolomics can help you streamline your drug development process by providing the framework to make a stronger, more confident, and more valuable case for a molecule in a shorter timeframe. Sponsored by: Epsilon Download this e-book to learn 9 ways to enhance the customer experience within healthcare marketing. Sponsored by: Reprints Desk/Research Solutions 3 ways you may be overspending on scientific literature access, and how to fix them. Sponsored by: Baxter When different drug products are produced in shared facilities, potential for cross-contamination needs to be addressed. Outsourcing to a CMO with experience in multiproduct facilities can be an option. Sponsored by: WCG Metrics Champion Consortium Ineffective measurement could mean wasting both time and money. This whitepaper showcases a custom-built Metric Maturity Model that helps illustrate and define the process for measuring the right things the right way. Sponsored by: Eagle Productivity Solutions Mediocre adoption rates aren’t due to poorly designed software or lazy users. They’re the result of how skills are trained. Achieve high adoption rates by implementing the right methodology with a focus on behavior change. Sponsored by: The Kinetix Group Read about the innovative ways payers are making smart moves in the healthcare game. Sponsored by: H1 Biopharma companies don't want to go to market with a product no one knows about. H1 has homed in on the often time-consuming research and engagement phases that companies must ace for a successful launch, said Ariel Katz, co-founder of H1. Sponsored by: Clinical Ink Download this free white paper to learn how a BYOD ePRO approach is beneficial to your trial. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Accenture Kevin Julian, senior managing director of Accenture’s life sciences practice, recently sat down with FierceBiotech to discuss market trends and Accenture’s new technology platform, INTIENT. Sponsored by: Blue Matter Consulting White paper describing how a biopharma company can successfully differentiate an oncology product when the clinical profile alone is not enough to get the job done. Sponsored by: Catalent Get expert insights on strategies to implement flexible manufacturing and different technologies that are easily scalable and reproducible. Sponsored by: Catalent Regardless of the assigned FDA expedited approval designation and approach, the key action items should be: the assurance of a detail-oriented plan and the adaption of a “forward-thinking” approach that will assist in any future challenges and opportunities for growth of each project. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. Bioprocessing Summit Europe – Practical Solutions for Today’s Bioprocess Challenges March 24-26 2020 | Barcelona, Spain BioBasics 101: The Biology of Biotech March 26-27, 2020 | Boston, MA Clinical Trial Innovation Summit – Technology, Data, Operations, Oversight April 6-8, 2020 | Cambridge, MA Drug Discovery Chemistry – Choose from 45 Presentations from Top Pharma April 13-17, 2020 | San Diego, CA Medical Affairs Strategic Summit (MASS) East April 14-16, 2020 | New Brunswick, NJ BioBasics 101: The Biology of Biotech April 16-17, 2020 | Philadelphia, PA Drug Development Immersion April 23-24, 2020 | Boston, MA 2nd Annual World Pharma Week: Driving Innovation in Drug R&D June 2-4, 2020 | Boston, MA European Healthcare Compliance Certificate Program June 2-5, 2020 | Paris, France BIO International Convention June 8-11, 2020 | San Diego, CA U.S. Healthcare Compliance Certificate Program June 8-10, 2020 | Newark, NJ Drug Development Boot Camp® 2020 November 18-19, 2020 | Register now and begin Pre-Boot Camp Preparation. | Take your new medicine development skills to the next level. | 